SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Caro Holdings entered into an Asset Purchase and Acquisition Agreement to acquire a 49% interest in mining properties in Tanzania, funded through the issuance of 20,000,000 shares of common stock to Goldrange.
View raw filing on EDGAR →This press release announces Phase III clinical trial results for sovleplenib (ESLIM-02 study) in warm antibody autoimmune hemolytic anemia, presented at EHA 2026 Congress. The disclosure highlights that the study met its primary endpoint with statistically significant efficacy data (66% durable response vs 15% placebo, p<0.0001) and a favorable safety profile. While this is a clinical milestone rather than financial results, it represents a material operational and regulatory event: the NMPA has accepted the NDA for priority review and granted Breakthrough Therapy Designation, positioning sovleplenib as a potential commercial product addressing an unmet medical need in a treatment-sparse landscape. The data directly supports regulatory advancement and future revenue potential.
View raw filing on EDGAR →GSK announced that momelotinib received Orphan Drug Designations (ODD) from the FDA and EMA for VEXAS syndrome treatment, with a planned phase II/III ATLAS trial underway. This is a material regulatory milestone for a rare disease indication that would affect investor assessment of the company's pipeline and development strategy, but it does not fit the specific event categories (not an earnings release, M&A activity, executive change, debt issuance, or other named types). The ODD designation and trial advancement represent a significant operational/strategic development in the drug's regulatory pathway.
View raw filing on EDGAR →Noble Romans entered into a material senior secured term loan agreement with Lake Forest Bank & Trust Company on June 10, 2026, for $6.9 million, and simultaneously terminated a prior material definitive agreement. The loan proceeds were used to refinance existing debt obligations, redeem warrants, and pay advisory fees, materially restructuring the company's capital structure and debt obligations.
View raw filing on EDGAR →This exhibit discloses the results of the Company's Annual General Meeting held on June 9, 2026, with detailed voting outcomes on four resolutions: cancellation of Ms. Jannu Binti Babjan's directorship, appointment of Mr. Uwe Henke von Parpart as director, approval of an Employee Stock Option Plan, and consolidation of capital. All resolutions were approved by greater than 50% of shareholders present by polls, making this a clear shareholder_vote_results disclosure.
View raw filing on EDGAR →HF Foods adopted a shareholder rights plan (poison pill) on June 12, 2026, with one Right per share exercisable at $9.55 per one one-thousandth of a share of Series AA Participating Preferred Stock. The plan is triggered by any person or group acquiring 15% or more of Common Stock without Board approval and is designed to deter hostile takeovers by imposing a significant penalty on such acquirers.
View raw filing on EDGAR →The exhibit discloses utilization of an "At the Market" (ATM) sales agreement with Cantor Fitzgerald & Co, announced December 17, 2024. Although no securities were actually issued during the reporting period (December 16, 2025 to June 12, 2026), the disclosure reports on the block admission of 4,000,000 depositary interests representing common shares available under the ATM scheme. ATM agreements represent standing authority to issue equity on a dilutive basis and are material capital-raising mechanisms, particularly for smaller issuers, even when no shares are issued in a given period.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the results of the Company's Annual Meeting of Stockholders held on June 11, 2026, reporting the election of four directors (Andrey Semechkin, Russell Kern, Donald A. Wright, and Paul V. Maier) with vote tallies showing overwhelming support. Director elections are material governance events affecting the composition of the board and thus the registrant's oversight and strategic direction.
View raw filing on EDGAR →Delta Air Lines entered into a new $2.65 billion credit facility on June 11, 2026, which refinances and replaces its existing credit agreement dated November 6, 2023. The facility includes financial covenants, an accordion feature allowing expansion to $3.65 billion, and customary events of default, constituting a material refinancing transaction affecting the company's capital structure and financial flexibility.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Praxis Precision Medicines' 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing presents voting results for three proposals: election of Class III directors (Gregory Norden, Marcio Souza, and William Young), ratification of Ernst & Young LLP as independent auditor, and an advisory vote on executive compensation. All three proposals passed with substantial majorities, making this a material shareholder vote results disclosure.
View raw filing on EDGAR →The company disclosed interim responder analysis data from a Phase 3 clinical trial (CAPTIVATE) for claseprubart in CIDP via an updated corporate presentation posted to its investor relations website. While clinical trial data updates can be material to investors evaluating the company's pipeline and regulatory prospects, this disclosure does not fit neatly into the more specific event categories (e.g., it is not a formal earnings release, M&A activity, or executive change). The interim nature and presentation format suggest this is a material clinical milestone, warranting classification as other_material rather than forcing it into an ill-fitting category.
View raw filing on EDGAR →This Item 5.07 discloses the results of Optimum Communications' 2026 Annual Meeting of Stockholders held on June 10, 2026, including voting tallies for the election of nine directors (Patrick Drahi, David Drahi, Dexter Goei, Dennis Mathew, Mark Mullen, Dennis Okhuijsen, Susan Schnabel, Charles Stewart, and Raymond Svider) and ratification of KPMG LLP as independent auditor. The detailed vote counts for and against each proposal are provided, making this a clear shareholder_vote_results disclosure. Board composition and auditor ratification are material to investors' assessment of governance and financial oversight.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from AbCellera's Annual Meeting of Shareholders held on June 11, 2026. The filing reports voting outcomes for three proposals: (i) election of two Class III directors (John S. Montalbano and Stephen R. Quake), (ii) ratification of Ernst & Young LLP as independent auditor, and (iii) advisory approval of named executive officer compensation. All three proposals were approved by shareholders, with detailed vote tallies provided for each. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms board composition and auditor ratification.
View raw filing on EDGAR →Angi Inc. held its Annual Meeting of Stockholders on June 10, 2026, with shareholders voting on three proposals: election of three Class II directors (Sandra Buchanan, Thomas C. Pickett Jr., and Glenn H. Schiffman), approval of the amended and restated 2017 Stock Plan, and ratification of Ernst & Young LLP as independent auditor. All three proposals passed with disclosed vote tallies.
View raw filing on EDGAR →Stockholders voted at the Annual Meeting on four proposals: election of six directors, advisory vote on executive compensation, approval of the Third Amended and Restated Omnibus Incentive Plan (increasing share pool by 2.5 million shares and extending the plan to 2036), and ratification of Grant Thornton as independent auditor. All proposals passed.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Arcus Biosciences' June 11, 2026 annual meeting, covering three proposals: election of Class II directors (Dietmar Berger, David Lacey, Nicole Lambert, and Johanna Mercier), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents detailed vote tallies (votes for, against, withheld, abstentions, and broker non-votes) for each proposal, which is the standard format for Item 5.07 disclosures and constitutes material information about corporate governance outcomes.
View raw filing on EDGAR →The disclosure centers on Amendment No. 1 to Danny Rittman's employment agreement as CTO/CISO, which modifies his compensation through: (1) a base salary increase to $180,000 effective June 1, 2026; and (2) a grant of 1,000,000 performance-based stock options at $4.98/share with milestone-based vesting tied to technical deliverables (VisionRF data room, StratumAI agent release, cybersecurity framework, and EDA strategy room). While the title update is noted, the substantive disclosure is compensatory in nature—salary adjustment and equity grant—making this an exec_compensation event rather than appointment or departure.
View raw filing on EDGAR →Sadot Group entered into a Written Option Agreement granting an exclusive, irrevocable six-month option to acquire 100% of membership interests in seven California-based real estate LLCs representing 147 residential units with a total agreed portfolio value of $125.5 million and equity value of $69.5 million.
View raw filing on EDGAR →The Company issued 132,803 shares of Common Stock (17.71% of outstanding shares) on June 6, 2026, as payment for an Option Fee under the Option Agreement, pursuant to Section 4(a)(2) of the Securities Act as an unregistered private placement to an accredited investor.
View raw filing on EDGAR →Splash Beverage Group invested $217,479.24 to acquire 2,000,000 common shares and 1,000,000 warrants of Avicanna Inc. in a private placement, representing a strategic capital allocation aligned with the Company's pivot into a cannabinoid-based platform.
View raw filing on EDGAR →Michael Bondurant was appointed as Chief Operating Officer, effective June 8, 2026. The appointment also includes compensatory arrangements for Bondurant and Brady Cobb (base salary, performance bonuses, and stock option grants) and adoption of an RSU Plan.
View raw filing on EDGAR →Jason Pernell, President of Trulieve Cannabis Corp., terminated his employment effective immediately on June 11, 2026, pursuant to a mutual agreement and Separation Agreement. The disclosure centers on the departure of a named executive officer from a senior position, with associated severance arrangements including cash payment, COBRA continuation, and equity vesting. This is a material executive departure that would affect investor assessment of the company's leadership and operational continuity.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Opendoor's 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing reports voting outcomes for three proposals: election of three Class III directors (David Benson, Eric Feder, Eric Wu), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Clover Health's June 10, 2026 Annual Meeting of Stockholders. The filing reports final voting tallies on three proposals: election of three Class II directors (Kouzoukas, Toy, and Tran), a non-binding advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. All three proposals passed with substantial majorities. Shareholder meeting outcomes are material to investors as they determine board composition and affirm key governance decisions.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from LENZ Therapeutics' 2026 annual meeting held on June 12, 2026. The filing reports voting outcomes for two matters: (1) election of three Class II directors (Evert Schimmelpennink, Jeff George, and Shelley Thunen), and (2) ratification of Ernst & Young LLP as independent auditor. The tabulated vote counts for each nominee and proposal are the core content of Item 5.07, which is the standard Item for reporting annual meeting results.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Playtika's annual meeting of stockholders held on June 11, 2026, including voting outcomes for three proposals: election of six directors, ratification of the independent auditor (Kost Forer Gabbay & Kasierer), and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a standard shareholder vote results disclosure that is material to investors' understanding of corporate governance.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Enovix's 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting outcomes for three proposals: election of eight directors, advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. All three proposals were approved by stockholders with detailed vote tallies (For, Against, Abstain, and Broker Non-Votes). This is a material disclosure as it documents shareholder approval of the board composition and executive compensation arrangements.
View raw filing on EDGAR →NEONC Technologies entered into a Securities Purchase Agreement to issue up to $5,000,000 of Series A Convertible Preferred Stock in a private placement to accredited investors under Section 4(a)(2) and Regulation D Rule 506 exemptions. The 6,000 shares of Series A Preferred Stock carry conversion rights into common stock at 80% of the lowest closing price during the five trading days prior to conversion, subject to a beneficial ownership limitation of 4.99% (or 9.99% upon election), resulting in material dilution to existing common shareholders.
View raw filing on EDGAR →The Company issued an unsecured promissory note of $191,475 to its sponsor to fund a trust account extension, creating a direct financial obligation with conditional forgiveness and conversion rights that affects the Company's capital structure and timeline for completing its initial business combination.
View raw filing on EDGAR →The Company issued an unregistered convertible note with underlying Units issuable upon conversion, subject to registration rights and transfer restrictions tied to the initial business combination, representing a dilutive issuance of equity securities.
View raw filing on EDGAR →The Company extended its Business Combination Deadline from June 13, 2026 to July 13, 2026 for its merger with MicroTouch Technology Inc., a governance action that materially affects the transaction timeline and likelihood of consummation.
View raw filing on EDGAR →Aeries Technology effected a 1-for-8 reverse share consolidation through an amendment to its Articles of Association, reducing outstanding Class A ordinary shares from approximately 45.9 million to 5.7 million. In connection with this capital structure change, the Company adjusted warrant terms by reducing the shares issuable per warrant to 1/8th and increasing the exercise price eight-fold to $92.00 per share.
View raw filing on EDGAR →The filing discloses equity option grants to named executives and directors under the 2021 Incentive Stock Plan. Ian Bothwell (CEO/CFO), George Shapiro (Chief Medical Officer), and non-executive director Chuck Bretz each received option awards totaling 625,000 to 1,250,000 shares at $1.67 per share. This is a compensatory arrangement for officers and directors, the core subject matter of Item 5.02(e), and materially affects executive compensation structure.
View raw filing on EDGAR →Titan Acquisition Corp entered into a Business Combination Agreement with OpenPayd Global Holdings Limited and related parties on June 1, 2026, with a first amendment executed on June 11, 2026. This constitutes a material acquisition/change of control transaction typical of SPAC business combinations, disclosed under Item 1.01 (Entry into a Material Definitive Agreement). The amendment clarifies warrant redemption procedures, confirming the parties' commitment to completing the acquisition.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Coupang's June 11, 2026 Annual Meeting of Stockholders. The filing reports voting outcomes on three proposals: (1) election of seven directors, (2) ratification of Samil PricewaterhouseCoopers as independent auditor, and (3) advisory approval of named executive officer compensation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Krispy Kreme's June 10, 2026 annual meeting. The filing presents detailed voting tallies for four proposals: election of eight directors, advisory approval of executive compensation, ratification of Grant Thornton LLP as auditor, and approval of the 2021 Omnibus Incentive Plan amendment. All proposals passed with substantial majorities, making this a material governance event that investors rely on to assess board composition and compensation oversight.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Lineage's June 9, 2026 annual meeting of stockholders. The filing presents final vote tallies for three proposals: (i) election of all ten director nominees, (ii) ratification of PricewaterhouseCoopers LLP as independent auditor, and (iii) advisory approval of named executive officer compensation. This is the quintessential Item 5.07 disclosure and directly matches the shareholder_vote_results event type.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Portillo's 2026 Annual Meeting of Shareholders held on June 9, 2026. The filing reports final voting tallies for three proposals: (i) election of seven directors, (ii) advisory approval of Named Executive Officer compensation, and (iii) ratification of Deloitte & Touche LLP as independent auditor. This is a textbook Item 5.07 disclosure and is material to investors as it documents the outcomes of fundamental corporate governance matters.
View raw filing on EDGAR →Rajeev Date's resignation as Lead Independent Director effective immediately is the principal disclosed action. While the filing also mentions Craig Broderick's appointment as the new Lead Independent Director, the core event centers on Date's departure after nearly 13 years of service, including his role as Lead Independent Director since November 2024. The departure of a long-tenured lead independent director is material to investors assessing board governance and continuity.
View raw filing on EDGAR →Noble Finance II LLC, a wholly owned subsidiary of Noble Corporation plc, entered into an indenture on June 11, 2026, issuing $800 million in aggregate principal amount of 6.250% Senior Notes due 2034. This material capital structure event includes extensive covenants and events of default that materially restrict the company's operational and financial flexibility.
View raw filing on EDGAR →The filing announces a general meeting of shareholders scheduled for 23 July 2026 to vote on a proposed $2.0 billion share repurchase programme previously approved by the Board on 7 May 2026. While this is technically a notice of a future shareholder vote rather than results of a completed vote, the disclosure of a material shareholder action (approval of a significant capital allocation program) is a governance event that would affect investor assessment. The $2.0bn repurchase is material to the company's capital allocation and shareholder returns.
View raw filing on EDGAR →The exhibit discloses results of an Extraordinary General Meeting held on 11 June 2026, with shareholder approval of three resolutions: agenda approval, dividend payment of KZT 850 per share for 1Q 2026, and election of three members to the Counting commission. This is a classic shareholder vote result disclosure (Item 5.07 equivalent), material because it announces a dividend distribution and governance appointments approved by shareholders.
View raw filing on EDGAR →The filing discloses entry into material definitive agreements on June 9, 2026: a Second Amended and Restated Trust Agreement and an Amended and Restated Sponsor Agreement. While Item 1.01 nominally covers M&A activity, these agreements fundamentally restructure the Trust's governance and compensation arrangements, particularly by authorizing staking programs and directing all staking rewards to the Sponsor outside the Trust's NAV. This is a material governance and economic restructuring affecting shareholder interests, but does not fit cleanly into the M&A taxonomy (no acquisition, merger, or disposition). The event is material to investors as it alters the economic terms and control structure of the ETF.
View raw filing on EDGAR →The Fund's Board of Trustees renewed an open-market share repurchase program authorizing purchases of up to 5% of outstanding common shares through June 30, 2027. While share repurchase programs are material to investors as they affect share count, capital allocation, and potential accretion/dilution, this disclosure does not fit neatly into the more specific event categories (it is neither a dilutive issuance, executive compensation, nor M&A activity). The renewal of a repurchase authorization is a governance and capital allocation decision material to shareholders but best classified as other_material.
View raw filing on EDGAR →The Fund's Board of Trustees renewed an open-market share repurchase program authorizing purchases of up to 5% of outstanding common shares through June 30, 2027. While share repurchase programs are routine for closed-end funds seeking to manage discount-to-NAV dynamics, the renewal and authorization of a material repurchase capacity (5% of shares) would affect investor assessment of capital allocation and share price support. This does not fit neatly into the more specific event categories but represents a material corporate action disclosed under Item 8.01.
View raw filing on EDGAR →The Fund's Board of Trustees renewed an open-market share repurchase program authorizing purchases of up to 5% of outstanding common shares through June 30, 2027. While share repurchase programs are routine for closed-end funds seeking to manage discount-to-NAV dynamics, the renewal and authorization of a material repurchase capacity (5% of shares) would be material to investors assessing capital allocation and potential accretion/dilution. This does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation), so "other_material" is most appropriate.
View raw filing on EDGAR →This Item 5.07 filing discloses the final voting results from MercadoLibre's Annual Meeting of Stockholders held on June 9, 2026. The section presents detailed vote tallies for three proposals: election of Class I directors (with individual vote counts for each nominee), advisory approval of named executive officer compensation, and ratification of the independent auditor (Pistrelli, Henry Martin y Asociados S.A.). All three proposals passed. This is a standard shareholder vote results disclosure that materially informs investors of governance outcomes and stakeholder approval of key corporate matters.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of American Integrity Insurance Group's annual meeting of stockholders held on June 11, 2026. The filing presents voting results for four proposals: election of director Steven Smathers, ratification of Forvis Mazars as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. All proposals received sufficient votes for approval. This is material as it documents stockholder actions on governance and audit matters.
View raw filing on EDGAR →The filing discloses the appointment of Collin Gallagher to the Board as a Class III director effective June 12, 2026, designated by Thoma Bravo pursuant to a Director Designation Agreement. While the section also mentions Nabil Hamade's resignation, the principal disclosed action centers on the appointment of a new director to fill the vacancy. Board composition changes are material to investors assessing corporate governance and control.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the results of Medline Inc.'s 2026 Annual Meeting of Stockholders held on June 11, 2026, including voting outcomes on four matters: election of 12 directors, advisory approval of executive compensation, frequency of advisory compensation votes (approved for annual frequency), and ratification of Ernst & Young LLP as independent auditor. The detailed vote tallies for each director and each proposal are provided, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →